Bruker Corporation Common Stock BRKR
i
Market dataready · fetched 2026-11-13T19:12:52.827Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T19:12:23.84090015Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T19:12:52.277973+00:00
Bruker Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 67.86 | 84.5% | 12.5% | 56.27 | 75.7% | 9.2% |
| 25Δ | 56.94 | 82.9% | 8.6% | |||
| 30Δ | 64.24 | 63.2% | 6.9% | 57.65 | 88.9% | 8.0% |
| 35Δ | 63.44 | 62.8% | 6.0% | 58.64 | 87.9% | 7.0% |
| 40Δ | 62.64 | 62.4% | 5.0% | 59.62 | 87.0% | 6.0% |
| 45Δ | 61.99 | 59.8% | 4.3% | 60.55 | 85.9% | 5.1% |
| 50Δ | 61.38 | 56.8% | 3.6% | 61.45 | 84.7% | 4.4% |
| 55Δ | 60.76 | 53.9% | 2.9% | 62.35 | 83.5% | 3.6% |
| 60Δ | 60.14 | 50.9% | 2.2% | 63.37 | 84.6% | 3.1% |
| 65Δ | 59.57 | 49.5% | 1.8% | 64.42 | 86.1% | 2.6% |
| 70Δ | 59.00 | 48.6% | 1.5% | 65.72 | 89.5% | 2.1% |
| 75Δ | 58.44 | 47.7% | 1.2% | 67.33 | 95.2% | 1.8% |
| 80Δ | 57.87 | 46.8% | 0.9% | 70.56 | 113.3% | 1.5% |
20Δ
- Pseudo strike
- 67.86
- IV
- 84.5%
- B/E move
- 12.5%
- Pseudo strike
- 56.27
- IV
- 75.7%
- B/E move
- 9.2%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 56.94
- IV
- 82.9%
- B/E move
- 8.6%
30Δ
- Pseudo strike
- 64.24
- IV
- 63.2%
- B/E move
- 6.9%
- Pseudo strike
- 57.65
- IV
- 88.9%
- B/E move
- 8.0%
35Δ
- Pseudo strike
- 63.44
- IV
- 62.8%
- B/E move
- 6.0%
- Pseudo strike
- 58.64
- IV
- 87.9%
- B/E move
- 7.0%
40Δ
- Pseudo strike
- 62.64
- IV
- 62.4%
- B/E move
- 5.0%
- Pseudo strike
- 59.62
- IV
- 87.0%
- B/E move
- 6.0%
45Δ
- Pseudo strike
- 61.99
- IV
- 59.8%
- B/E move
- 4.3%
- Pseudo strike
- 60.55
- IV
- 85.9%
- B/E move
- 5.1%
50Δ
- Pseudo strike
- 61.38
- IV
- 56.8%
- B/E move
- 3.6%
- Pseudo strike
- 61.45
- IV
- 84.7%
- B/E move
- 4.4%
55Δ
- Pseudo strike
- 60.76
- IV
- 53.9%
- B/E move
- 2.9%
- Pseudo strike
- 62.35
- IV
- 83.5%
- B/E move
- 3.6%
60Δ
- Pseudo strike
- 60.14
- IV
- 50.9%
- B/E move
- 2.2%
- Pseudo strike
- 63.37
- IV
- 84.6%
- B/E move
- 3.1%
65Δ
- Pseudo strike
- 59.57
- IV
- 49.5%
- B/E move
- 1.8%
- Pseudo strike
- 64.42
- IV
- 86.1%
- B/E move
- 2.6%
70Δ
- Pseudo strike
- 59.00
- IV
- 48.6%
- B/E move
- 1.5%
- Pseudo strike
- 65.72
- IV
- 89.5%
- B/E move
- 2.1%
75Δ
- Pseudo strike
- 58.44
- IV
- 47.7%
- B/E move
- 1.2%
- Pseudo strike
- 67.33
- IV
- 95.2%
- B/E move
- 1.8%
80Δ
- Pseudo strike
- 57.87
- IV
- 46.8%
- B/E move
- 0.9%
- Pseudo strike
- 70.56
- IV
- 113.3%
- B/E move
- 1.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 55.18% | |
| 54.87% | |
| 57.54% | |
| 61.56% | |
| 52.53% | |
| 53.61% | |
| 54.76% | |
| 53.27% | |
| 52.53% | |
| 52.36% | |
| 53.54% | |
| 53.88% | |
| 53.18% | |
| 51.57% | |
| 52.55% | |
| 55.57% | |
| 55.74% | |
| 55.57% | |
| 56.03% | |
| 62.00% | |
| 59.03% | |
| 60.78% | |
| 63.48% | |
| 56.01% | |
| 56.69% | |
| 55.43% | |
| 57.61% | |
| 59.80% | |
| 62.09% | |
| 65.12% | |
| 63.32% | |
| 62.38% | |
| 62.69% | |
| 60.64% | |
| 59.44% | |
| 61.35% | |
| 60.00% | |
| 62.24% | |
| 61.50% | |
| 63.82% | |
| 67.72% | |
| 70.21% | |
| 73.59% | |
| 60.99% | |
| 61.23% | |
| 59.54% | |
| 60.05% | |
| 61.55% | |
| 60.26% | |
| 62.97% | |
| 61.04% | |
| 59.24% | |
| 62.27% | |
| 64.03% |
Medical Devices
BSX
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional…
More →BVS
Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United…
More →BWAY
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company…
More →CATX
Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals.…
More →CBLL
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in…
More →CERS
Description unavailable
More →